\
&
Contact us
\
&
Contact us
Published on | 3 weeks ago
Programmes EIT28DIGITAL, formerly known as EIT Digital, is moving forward while maintaining collaboration with the European Institute of Innovation and Technology (EIT) under a Memorandum of Collaboration.
Each knowledge and innovation community (KIC) has a financial support life cycle of maximum 15 years after which it no longer receives funding from the European Commission. EIT Digital is one of the three KIC's that now makes the step to independency. To highlight this milestone, they have decided to rebrand themselves.
For more information on 28DIGITAL's initiatives and partnerships, visit their new website at https://www.28digital.eu.
Background: The European institute of Innovation and Technology stands at the crossroad of business creation, innovation and education. It consists of ten knowledge and innovation communities of which the EIT urban mobility is one of them. The overal objective is to transform promising innovations into succesful companies
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
